Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 9 of 12 for:    cook myosite

Autologous Cell Therapy for Treatment of Fecal Incontinence

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01600755
Recruitment Status : Completed
First Posted : May 17, 2012
Last Update Posted : December 10, 2021
Sponsor:
Information provided by (Responsible Party):
Cook MyoSite

Brief Summary:
The aim of this clinical study is to investigate the safety and feasibility of Autologous Muscle Derived Cells (AMDC; a preparation of a patient's own cells) injection into the anal sphincter for treatment of patients with fecal incontinence.

Condition or disease Intervention/treatment Phase
Fecal Incontinence Biological: Autologous Muscle-Derived Cells (AMDC) Phase 1 Phase 2

Detailed Description:
This study is designed to test the safety and feasibility of Autologous Muscle Derived Cells (AMDC) as a treatment for fecal incontinence in men and women. AMDC therapy seeks to allow remodeling of the external anal sphincter in patients with fecal incontinence from either defined structural defects to or a generalized weakening of the external anal sphincter.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 53 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective Nonrandomized Study of Autologous Muscle Derived Cell (AMDC) Transplantation for Treatment of Fecal Incontinence
Actual Study Start Date : May 2012
Actual Primary Completion Date : October 27, 2021
Actual Study Completion Date : October 27, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bowel Movement

Arm Intervention/treatment
Experimental: Autologous Muscle-Derived Cells
Cell Treatment
Biological: Autologous Muscle-Derived Cells (AMDC)
Cell Treatment




Primary Outcome Measures :
  1. Incidence of Treatment-Related Adverse Events [ Time Frame: 12 months ]

Secondary Outcome Measures :
  1. Frequency of Incontinent Episodes [ Time Frame: 12 Months ]
  2. Incontinence Score [ Time Frame: 12 Months ]
  3. Sphincter Pressure [ Time Frame: 12 Months ]
  4. Fecal Incontinence Quality of Life Scale (FIQL) [ Time Frame: 12 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Primary symptoms of fecal incontinence, as confirmed by patient medical history and physical examination
  • Wexner score ≥ 9
  • Failed conservative treatment

Exclusion Criteria:

  • Gracilis sling repair or insertion of an artificial sphincter
  • Inflammatory Bowel Disease
  • Significant rectocele or rectal prolapse
  • History of radiation treatment to the anal sphincter or adjacent structures
  • Less than 18 years of age
  • Pregnant, breastfeeding, or plans to become pregnant during the course of the study
  • Neuromuscular disorder
  • History of neoplasia within 5 years prior to enrollment, except for basal cell carcinoma, or is receiving or planning to receive anti-cancer medications
  • Known bleeding diathesis or uncorrected coagulopathy
  • Medical condition that would preclude treatment due to contraindications and/or warnings of concomitant medications or listed in the experimental product labeling
  • Participating in another investigational drug or device study
  • Unable or unwilling to provide informed consent
  • Unable or unwilling to commit to the follow-up procedures

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01600755


Locations
Layout table for location information
Canada, British Columbia
St. Paul's Hospital
Vancouver, British Columbia, Canada, V6Z 1Y6
United Kingdom
Royal London Hospital
London, United Kingdom
Sponsors and Collaborators
Cook MyoSite
Investigators
Layout table for investigator information
Principal Investigator: Manoj J Raval, MD St. Paul's Hospital
Layout table for additonal information
Responsible Party: Cook MyoSite
ClinicalTrials.gov Identifier: NCT01600755    
Other Study ID Numbers: 09-025
First Posted: May 17, 2012    Key Record Dates
Last Update Posted: December 10, 2021
Last Verified: December 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Cook MyoSite:
Cell Therapy
Autologous Cell Transplantation
Muscle-derived Cell
Anal Incontinence
Rectal Diseases
Intestinal Diseases
Gastrointestinal Diseases
Urinary Incontinence
Additional relevant MeSH terms:
Layout table for MeSH terms
Fecal Incontinence
Rectal Diseases
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases